Healthcare Stocks

Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

 Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

Summary Imugene Limited (ASX:IMU) completes the enrolment of three patients under the first cohort under PD1-Vaxx Phase I clinical trial. Following the Phase I trial, a monotherapy optimal biological dose will be determined through a review by ...

Read More...
Imugene Receives Core US Patent for its Cancer Growth Factor Immunotherapy Platform

Imugene Receives Core US Patent for its Cancer Growth Factor Immunotherapy Platform

Summary Imugene has attained a core patent in the largest pharmaceutical market of the world. The patent protects its cancer growth factor immunotherapy platform, predominantly unique combination treatments that target members of the IGF-1R and...

Read More...
Imugene Appoints Dr Rita Laeufle as its New Chief Medical Officer; Stock Soars 8.5%

Imugene Appoints Dr Rita Laeufle as its New Chief Medical Officer; Stock Soars 8.5%

Summary Imugene has appointed Dr Rita Laeufle as its new Chief Medical Officer and a member of its executive leadership team. Dr Laeufle will lead the Company’s global clinical development, medical monitoring, and regulatory activities. ...

Read More...
Imugene Secures Option Underwriting Agreement with Bell Potter to Raise $5.7 Million

Imugene Secures Option Underwriting Agreement with Bell Potter to Raise $5.7 Million

NSW-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has secured an underwriting agreement with Bell Potter Securities Limited with institutional investors to underwrite the balance of options not exercised by 30 Novembe...

Read More...
Imugene Attains First US Ethics Approval from WIRB to Begin PD1-Vaxx’s Phase I trial

Imugene Attains First US Ethics Approval from WIRB to Begin PD1-Vaxx’s Phase I trial

Australia-based immuno-oncology company Imugene Limited (ASX:IMU) has recently marked a great leap forward by attaining the first ethics approval in the US to kick-start Phase I trial of new cancer immunotherapy, PD1-Vaxx. The approval has been rec...

Read More...
Imugene’s FY20 Report Card Out, Outlines Notable Operational Achievements

Imugene’s FY20 Report Card Out, Outlines Notable Operational Achievements

In a latest update, the biotech company Imugene Limited (ASX:IMU) has published its Annual Report for the year ended 30th June 2020 on the ASX. The financial year 2020 has been a remarkable one for Imugene, experiencing significant change and growt...

Read More...
Imugene Receives Third Ethics Approval for PD1-Vaxx’s Phase 1 Trial in Australia

Imugene Receives Third Ethics Approval for PD1-Vaxx’s Phase 1 Trial in Australia

The stock of Australian clinical-stage immuno-oncology company, Imugene Limited (ASX:IMU) traded ~1.8 per cent higher on 21st August 2020 following the release of a significant update on PD1-Vaxx’s third ethics approval for Phase 1 trial. To...

Read More...
Imugene Received FDA Guidance for VAXinia’s Clinical Development Pathway

Imugene Received FDA Guidance for VAXinia’s Clinical Development Pathway

Summary Imugene received US FDA guidance on the development pathway for VAXinia (CF33-hNIS). FDA provided feedback on adaptive Phase 1 clinical development plans and non-clinical development pathway for VAXinia. The Company has initiated regul...

Read More...
Flick Through Imugene’s June 2020 Quarter Milestones

Flick Through Imugene’s June 2020 Quarter Milestones

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU) marked an uptick of ~22.6 per cent to $0.065 on ASX following the release of its solid June quarterly results on 27 July 2020. As at 11:50 AM AEST on 29 July 2020, IMU is trading at ...

Read More...
Imugene Receives Second Ethics Approval to Commence PD1-Vaxx Phase 1 Trial, Stock Soars 8%

Imugene Receives Second Ethics Approval to Commence PD1-Vaxx Phase 1 Trial, Stock Soars 8%

Clinical stage immuno-oncology firm based in Australia, Imugene Limited (ASX:IMU) has received a second human research ethics approval from the Sydney-based Macquarie University Human Research Ethics Committee (HREC) to kickstart Phase I clinical t...

Read More...
Another String to Imugene’s Bow - Attains Ethics Approval for Initiation of PD1-Vaxx’ Phase 1 Clinical Trial

Another String to Imugene’s Bow - Attains Ethics Approval for Initiation of PD1-Vaxx’ Phase 1 Clinical Trial

Australian clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has attained a significant milestone with the receipt of ethics approval for Phase I clinical trial of anti-cancer immunotherapy, PD1-Vaxx. PD1-Vaxx is Imugene’s B-cel...

Read More...
Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK